February 1, 2011
Bookmark and Share  
 
  HCV
»
»
»
»

 

Greetings:

This week’s postings include:

February 2011 HCV Advocate newsletter that includes:

  • An article about the priority review given for boceprevir and telaprevir in the United States and the European Union.  In addition, telaprevir has been grant priority review in Canada.

  • “News Briefs” contains an overview of important news stories, including the first real collaboration between HCV pharmaceuticals, new guidelines on acetaminophen dosage, pilot programs for the HCV aged-based testing initiatives, and the use of medicines to prevent the recurrence of hepatitis C after liver transplantation. 

  • “HCV Snapshots” for February are devoted to research on the association between HCV, stroke and heart disease,

  • “HealthWise”’s topic this month is a further exploration of the heart and HCV

February HBV Journal Review that includes: 

  • A push to increase the diagnosis of liver cancer

  • A new and more accurate liver cancer marker

  • Early identification of liver cancer = longer survival

  • Women with HBV and Non-Hodgkin Lymphoma cancer

  • First-line of treatment – pegylated interferon or HBV antivirals?

  • Liver disease and risk of stroke

                      …..and many more articles

 

Don’t forget to check out our blog for more about the most recent news stories.

 

 

Sincerely,
Alan

 

Alan Franciscus
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate www.hcvadvocate.org
Editor-in-Chief, HBV Advocate www.hbvadvocate.org

.

**Questions and Comments: Questions and/or comments can be directed to alanfranciscus@hcvadvocate.org

**To receive the eblast in your email inbox simply send an e-mail to: listserv@list.hcvadvocate.org with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.

.

  HBV
»
»
»
»